

Mu.Ta.Lig. COST Action speeds up the European Drug Discovery process



## 1st WG meeting – MuTaLig COST Action Hotel Novotel Budapest Danube - Budapest, November 19-20 2016

### **POLY-PHARMACOLOGY EXPANDING PAUL EHRLICH'S MAGIC BULLET CONCEPT**

[www.mutalig.eu](http://www.mutalig.eu)

**Saturday November 19<sup>st</sup> 2016**

- 8.30 Registration
- 9.00 **Introduction to the MuTaLig COST Action WG meeting**  
**Stefano ALCARO** (CA15135 Chair) - Università "Magna Græcia" di Catanzaro (Italy)  
**Session I "Experts' opinions on multi-targeting drug discovery"**  
**moderator Mátyus Péter (LOS & MC member for Hungary) - Semmelweis University, Budapest (Hungary)**
- 9.15 **PL1 Cariprazine: A short overview of newest pharmaceutical and medical milestone in the psychiatry**  
**György NÉMETH (invited speaker)** - Chemical Works of Gedeon Richter Plc., Hungary
- 10.00 **PL2 Through privileged scaffolds to multi-target drugs: isatin hybrids as anti-viral and anti-tumour agents**  
**Elias MACCIONI (invited speaker)** - University of Cagliari (Italy)
- 10.45 **PL3 En route to new anticancer agents based on the alkaloid Luotonin A**  
**Norbert HAIDER (invited speaker)** - University of Vienna (Austria)
- 11.30 *Coffee break*  
**Session II "Towards new chemical entities within WG1"**  
**Moderator Danijel KIKELJ (WG1 leader) - University of Ljubljana (Slovenia)**
- 12.00 Oral communications for the WG1 to be defined
- 13.30 *Lunch*  
**Session III "Development of chemical databases within WG2"**  
**Moderator Sharon BRYANT (WG3 leader) - Inte:Ligand GmbH, Vienna (Austria)**
- 14.30 Oral communications for the WG3 to be defined
- 16.00 *Coffee break*  
**Session IV "Development of Computational methods for multiple ligand design and discovery within WG4"**  
**Moderator Hanoch SENDEROWITZ (WG4 leader) - Bar-Ilan University, Ramat-Gan (Israel)**
- 16.30 Oral communications for the WG4 to be defined
- 20.00 *Social Dinner to be communicated*

**Sunday November 20<sup>st</sup> 2016**

- Session V "Selection of biological targets and assessment of biological data within WG2"**  
**Moderator Eugenio GAUDIO (WG2 leader) - Oncology Research Institute, Bellinzona (Switzerland)**
- 9.00 Oral communications for the WG2 to be defined
- 10.30 *Coffee break and Poster session*
- 11.30 **Round table "Status of the WG activities of MuTaLig COST Action"**  
**Moderator Fernanda BORGES (CA15135 Vice-Chair) - University of Porto (Portugal)**
- 13.00 **Concluding remarks**